Role of CBD in Regulating Meal Time Anxiety in Anorexia Nervosa
Launched by UNIVERSITY OF CALIFORNIA, SAN DIEGO · May 5, 2021
Trial Information
Current as of June 04, 2025
Active, not recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring the potential benefits of cannabidiol (CBD) for patients with Anorexia Nervosa (AN), particularly in managing anxiety around mealtime. CBD is a compound found in cannabis that has been shown to help reduce anxiety, and researchers want to see if it can also help people with AN, which is a serious eating disorder. This study is important because it is one of the first to look specifically at how CBD might work for those struggling with AN and how it affects their eating behaviors and weight.
To participate in this study, women aged 18 to 65 who have been diagnosed with Anorexia Nervosa or related disorders for at least six months may be eligible, provided they are medically stable. However, individuals with certain mental health conditions, substance dependencies, specific physical health issues, or those who have had recent changes in medication will not be included. Participants can expect to receive CBD and be closely monitored by medical professionals to assess its effects on their anxiety and eating habits. This research could help pave the way for new treatment options for those affected by Anorexia Nervosa.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • 1. Must currently meet DSM-5 criteria for AN-R and AN Spectrum Disorders (i.e., Atypical AN) based on the Structured Clinical Interview for the DSM-5 (SCID-5-RV)
- • 2. Have a duration of illness ≥ 6 months
- • 3. Be medically stable as assessed by a comprehensive medical and behavioral evaluation conducted by a study physician
- Exclusion Criteria:
- • 1. Psychotic illness/other mental illness requiring inpatient hospitalization
- • 2. Current dependence on drugs or alcohol
- • 3. Physical conditions (e.g., diabetes mellitus, pregnancy) known to influence eating or weight or liver disease which may affect pharmacokinetics of the study drug
- • 4. Use of other psychoactive medications
- • 5. Significant changes in medication in past month
- • 6. Expression of acute suicidality
- • 7. Previous hypersensitivity reaction to Epidiolex or any of its constituents
About University Of California, San Diego
The University of California, San Diego (UCSD) is a leading academic institution renowned for its commitment to advancing healthcare through innovative research and clinical trials. With a robust focus on translational medicine, UCSD leverages its interdisciplinary approach to explore groundbreaking therapies and interventions across a wide range of medical fields. The university's state-of-the-art facilities and collaboration with top-tier faculty and researchers ensure a comprehensive and ethical framework for conducting clinical trials, ultimately aiming to enhance patient outcomes and contribute to the global body of medical knowledge.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
San Diego, California, United States
Patients applied
Trial Officials
Guido K Frank, MD
Principal Investigator
University of California, San Diego
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials